Uğur Avcıbaşı
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Uğur Avcıbaşı has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Hasan Demiroğlu
Department of Chemistry, Faculty of Arts and Science, Celal Bayar University, Manisa, Turkey
4 shared publications- Fazilet Zumrut Biber Muftuler
Department of Nuclear Applications, Institute of Nuclear Sciences, Ege University, İzmir, Turkey
3 shared publications Melis Ediz
Department of Chemistry, Faculty of Arts and Science, Celal Bayar University, Manisa, Turkey
3 shared publications- Ceren Türkcan
BEYKENT ÜNİVERSİTES
2 shared publications - Emir Özçalışkan
B Faculty of Science, Department of Biochemistry , Ege University , Izmir , Turkey
2 shared publications Fikriye Gül Gümüşer
Department of Nuclear Medicine, Faculty of Medicine, Celal Bayar University, Manisa, Turkey
2 shared publications
Latest Publications
- 27 September 2013
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 15 (10) , 1-24
Synthesis and biodistribution of novel magnetic-poly(HEMA–APH) nanopolymer radiolabeled with iodine-131 and investigation its fate in vivo for cancer therapy
- 27 September 2013
- Published by Springer Nature in Journal of Nanoparticle Research
- Vol. 15 (10) , 1-24
Synthesis and biodistribution of novel magnetic-poly(HEMA–APH) nanopolymer radiolabeled with iodine-131 and investigation its fate in vivo for cancer therapy
- 19 August 2013
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 56 (14) , 708-716
Radiolabeling of new generation magnetic poly(HEMA–MAPA) nanoparticles with 131I and preliminary investigation of its radiopharmaceutical potential using albino Wistar rats
In this study, N‐methacryloyl‐l‐phenylalanine (MAPA) containing poly(2‐hydroxyethylmethacrylate) (HEMA)‐based magnetic poly(HEMA–MAPA) nanobeads [mag‐poly(HEMA–MAPA)] were radiolabeled with 131I [131I‐mag‐poly(HEMA–MAPA)], and the radiopharmaceutical potential of 131I‐mag‐poly(HEMA–MAPA) was investigated. Quality control studies were carried out by radiochromatographic method to be sure that 131I binded to mag‐poly(HEMA–MAPA) efficiently. In this sense, binding yield of 131I‐mag‐poly(HEMA–MAPA) was found to be about 95–100%. In addition to this, optimum radiodination conditions for 131I‐mag‐poly(HEMA–MAPA) were determined by thin‐layer radiochromatography studies. In addition to thin‐layer radiochromatography studies, lipophilicity (partition coefficient) and stability studies for 131I‐mag‐poly(HEMA–MAPA) were realized. It was determined that lipophilicities of mag‐poly(HEMA–MAPA) and 131I‐mag‐poly(HEMA–MAPA) were 0.12 ± 0.01 and 1.79 ± 0.76 according to ACD/logP algorithm program, respectively. Stability of the radiolabeled compound was investigated in time intervals given as 0, 30, 60, 180, and 1440 min. It was found that 131I‐mag‐poly(HEMA–MAPA) existed as a stable complex in rat serum within 60 min. After that, biodistribution and scintigraphy studies were carried out by using albino Wistar rats. It was determined that the most important 131I activity uptake was observed in the breast, the ovary, and the pancreas. Scintigraphy studies well supported biodistribution results. Copyright © 2013 John Wiley & Sons, Ltd.
- 19 August 2013
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 56 (14) , 708-716
Radiolabeling of new generation magnetic poly(HEMA–MAPA) nanoparticles with 131I and preliminary investigation of its radiopharmaceutical potential using albino Wistar rats
In this study, N‐methacryloyl‐l‐phenylalanine (MAPA) containing poly(2‐hydroxyethylmethacrylate) (HEMA)‐based magnetic poly(HEMA–MAPA) nanobeads [mag‐poly(HEMA–MAPA)] were radiolabeled with 131I [131I‐mag‐poly(HEMA–MAPA)], and the radiopharmaceutical potential of 131I‐mag‐poly(HEMA–MAPA) was investigated. Quality control studies were carried out by radiochromatographic method to be sure that 131I binded to mag‐poly(HEMA–MAPA) efficiently. In this sense, binding yield of 131I‐mag‐poly(HEMA–MAPA) was found to be about 95–100%. In addition to this, optimum radiodination conditions for 131I‐mag‐poly(HEMA–MAPA) were determined by thin‐layer radiochromatography studies. In addition to thin‐layer radiochromatography studies, lipophilicity (partition coefficient) and stability studies for 131I‐mag‐poly(HEMA–MAPA) were realized. It was determined that lipophilicities of mag‐poly(HEMA–MAPA) and 131I‐mag‐poly(HEMA–MAPA) were 0.12 ± 0.01 and 1.79 ± 0.76 according to ACD/logP algorithm program, respectively. Stability of the radiolabeled compound was investigated in time intervals given as 0, 30, 60, 180, and 1440 min. It was found that 131I‐mag‐poly(HEMA–MAPA) existed as a stable complex in rat serum within 60 min. After that, biodistribution and scintigraphy studies were carried out by using albino Wistar rats. It was determined that the most important 131I activity uptake was observed in the breast, the ovary, and the pancreas. Scintigraphy studies well supported biodistribution results. Copyright © 2013 John Wiley & Sons, Ltd.
- 1 May 2013
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 28 (4) , 310-319
Investigation of Therapeutic Efficiency of Bleomycin and Bleomycin-Glucuronide Labeled with 131 I on the Cancer Cell Lines
The aim of this study is to determine the incorporations of radiolabeled bleomycin (131I-BLM) and bleomycin-glucuronide (131I-BLMGLU) on PC-3 (human prostate carcinoma cell line), Caco-2 (human colon adenocarcinoma cell line), Hutu-80 (Human Duodenum adenocarcinoma cell line), and A549 (Human lung adenocarcinoma epithelial cell line) cancerous cell lines. For this purpose, BLM and BLMGLU enyzmatically synthesized were labeled with 131I, quality control studies were done and the incorporation yields of 131I-BLM and 131I-BLMGLU on these cell lines were measured. Quality-control studies showed that the radiolabeling yields were obtained as 95% and 90% for 131I-BLM and 131I-BLMGLU, respectively. Also, as a result of the cell culture studies, it was found that 131I-BLM and 131I-BLMGLU had higher incorporation on PC-3 cells than that of other cell lines. In addition to this, it was reported that the incorporation yield of 131I-BLMGLU was higher than that 131I-BLM. At the end of the study, cytotoxicities of BLM and BLMGLU on PC-3 cancerous cell line were inspected and fluorescent images of BLM and BLMGLU were taken on PC-3 cells by using fluorescein isothiocyanate. In conclusion, cell culture studies demonstrated that the incorporation values of 131I-BLMGLU on the four cell lines were about five to six times higher than 131I-BLM. Radiolabeled glucuronide derivatives can be used in cancer therapy and tumor imaging, depending on the properties of radioiodine for the β-glucuronidase-rich tissues because glucuronidation leads to rapid and higher incorporation on adenocarcinoma cells.
- 1 May 2013
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 28 (4) , 310-319
Investigation of Therapeutic Efficiency of Bleomycin and Bleomycin-Glucuronide Labeled with 131 I on the Cancer Cell Lines
The aim of this study is to determine the incorporations of radiolabeled bleomycin (131I-BLM) and bleomycin-glucuronide (131I-BLMGLU) on PC-3 (human prostate carcinoma cell line), Caco-2 (human colon adenocarcinoma cell line), Hutu-80 (Human Duodenum adenocarcinoma cell line), and A549 (Human lung adenocarcinoma epithelial cell line) cancerous cell lines. For this purpose, BLM and BLMGLU enyzmatically synthesized were labeled with 131I, quality control studies were done and the incorporation yields of 131I-BLM and 131I-BLMGLU on these cell lines were measured. Quality-control studies showed that the radiolabeling yields were obtained as 95% and 90% for 131I-BLM and 131I-BLMGLU, respectively. Also, as a result of the cell culture studies, it was found that 131I-BLM and 131I-BLMGLU had higher incorporation on PC-3 cells than that of other cell lines. In addition to this, it was reported that the incorporation yield of 131I-BLMGLU was higher than that 131I-BLM. At the end of the study, cytotoxicities of BLM and BLMGLU on PC-3 cancerous cell line were inspected and fluorescent images of BLM and BLMGLU were taken on PC-3 cells by using fluorescein isothiocyanate. In conclusion, cell culture studies demonstrated that the incorporation values of 131I-BLMGLU on the four cell lines were about five to six times higher than 131I-BLM. Radiolabeled glucuronide derivatives can be used in cancer therapy and tumor imaging, depending on the properties of radioiodine for the β-glucuronidase-rich tissues because glucuronidation leads to rapid and higher incorporation on adenocarcinoma cells.
- 1 October 2011
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 26 (5) , 573-584
Metabolic Comparison of Radiolabeled Bleomycin and Bleomycin-Glucuronide Labeled with 99m Tc
The metabolic comparison of bleomycin (BLM) and bleomycin-glucuronide (BLMG) radiolabeled with 99mTc (99mTc-BLM and 99mTc-BLMG, respectively) has been investigated in this study. Quality control procedures were carried out using thin-layer radiochromatography and high-performance liquid chromatography. To compare the metabolic behavior of BLM and its glucuronide conjugate radiolabeled with 99mTc, scintigraphic, and biodistributional techniques were applied using male New Zealand rabbits and Albino Wistar rats. The results obtained have shown that these compounds were successfully radiolabeled with a labeling yield of about 100%. Maximum uptakes of 99mTc-BLM and 99mTc-BLMG metabolized as N-glucuronide were observed within 2 hours in the liver, the bladder, and the spinal cord for 99mTc-BLM and the lung, the liver, the kidney, the large intestine, and the spinal cord for 99mTc-BLMG, respectively. Scintigraphy and biodistributional studies performed on the experimental animals have shown that radiopharmaceutical potentials of these compounds are completely different. At the same time, uptake of the 99mTc-BLMG was found to be better than that of 99mTc-BLM.
- 1 October 2011
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 26 (5) , 573-584
Metabolic Comparison of Radiolabeled Bleomycin and Bleomycin-Glucuronide Labeled with 99m Tc
The metabolic comparison of bleomycin (BLM) and bleomycin-glucuronide (BLMG) radiolabeled with 99mTc (99mTc-BLM and 99mTc-BLMG, respectively) has been investigated in this study. Quality control procedures were carried out using thin-layer radiochromatography and high-performance liquid chromatography. To compare the metabolic behavior of BLM and its glucuronide conjugate radiolabeled with 99mTc, scintigraphic, and biodistributional techniques were applied using male New Zealand rabbits and Albino Wistar rats. The results obtained have shown that these compounds were successfully radiolabeled with a labeling yield of about 100%. Maximum uptakes of 99mTc-BLM and 99mTc-BLMG metabolized as N-glucuronide were observed within 2 hours in the liver, the bladder, and the spinal cord for 99mTc-BLM and the lung, the liver, the kidney, the large intestine, and the spinal cord for 99mTc-BLMG, respectively. Scintigraphy and biodistributional studies performed on the experimental animals have shown that radiopharmaceutical potentials of these compounds are completely different. At the same time, uptake of the 99mTc-BLMG was found to be better than that of 99mTc-BLM.
- 1 May 2010
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 285 (2) , 207-214
In vivo biodistribution of 131I labeled bleomycin (BLM) and isomers (A2 and B2) on experimental animal models
- 1 May 2010
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 285 (2) , 207-214
In vivo biodistribution of 131I labeled bleomycin (BLM) and isomers (A2 and B2) on experimental animal models